Epirubicin: Clinical Pharmacology and Dose-Effect Relationship

Drugs

Volumn 45, Issue 2, 1993, Pages 20-30

  Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; CYCLOPHOSPHAMIDE; DOXORUBICINOL; DRUG METABOLITE; EPIRUBICINOL; FLUOROURACIL;

BREAST TUMOR; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HALF LIFE TIME; HUMAN; METABOLISM; REVIEW; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERANCE; DRUG URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; PLASMA CLEARANCE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; HALF-LIFE; HUMAN;

EID: 0027249853     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199300452-00005     Document Type: Article

References (68)

1. Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone
2. Experimental systemic toxicology of 4′-epidoxorubicin, a new less cardiotoxic anthracycline antitumor agent
3. High-dose 4′-epiadriamycin as primary treatment for advanced breast cancer. Abstract 72
4. Epirubicin in extensive small cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study
5. Phase II study of doxorubicin versus epirubicin in advanced breast cancer
6. Pharmacokinetic studies of 4′-epidoxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases
7. Epirubicin plasma and blood pharmacokinetics after single iv bolus in advanced cancer patients
8. Biliary excretion and pharmacokinetics of 4′-epidoxorubicin in advanced cancer patients
9. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study
10. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study
11. Experimental evaluation of anthracycline analogs
12. Phase I–II study of epirubicin in multiple myeloma
13. Phase I-II trial of high-dose epirubicin in patients with lymphoma
14. A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin
15. Comparative pharmacokinetic study of adriamycin and 4′-epiadriamycin after their simultaneous intravenous administration
16. A pharmacokinetic study of adriamycin and 4′-epiadriamycin after simultaneous intraarterial liver administration
17. High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer
18. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin
19. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
20. 4′-epidoxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data
21. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial
22. Epirubicin at two dose level with prednisolone as treatment for advanced breast cancer: the results of a randomized trial
23. Early assessment of a new anticancer drug analogue. Are the historical comparisons obsolete? The French experience with pirarubicin
24. A comparison of the lethal and kinetic effects of doxorubicin and 4′-epidoxorubicin in vitro
25. The importance of dose-response in cytotoxic therapy for breast cancer
26. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer
27. The importance of dose intensity in chemotherapy of metastatic breast cancer
28. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer
29. Pharmacokinetic and pharmacodynamic studies with 4′-epidoxorubicin in nasopharyngeal carcinoma patients
30. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer. An Italian multicenter trial
31. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
32. Multiple dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer
33. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood sample measurement
34. A phase II evaluation of 4′-epidoxorubicin in small cell lung cancer. Abstract
35. A phase I-II study of intensive dose adriamycin for advanced breast cancer
36. Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung
37. Comparative mammalian metabolism of adriamycin and daunomycin
38. High-dose epirubicin in combination with cyclophosphamide in advanced breast cancer: final results of a dose-finding study and phase II trial
39. High-dose epirubicin + cyclophosphamide as primary chemotherapy in stage III a/b breast cancer. Abstract 323
40. Crossover study of pharmacokinetics and haematological toxicity of 4′-epidoxorubicin in cancer patients
41. New cytotoxic drugs in treatment of breast cancer
42. Current status of epirubicin in the treatment of solid tumors
43. Absorption of epidoxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder
44. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in human
45. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification
46. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer
47. Conventional vs high-dose epirubicin as single agent in advanced breast cancer. Abstract 132
48. Dose-response evaluation of adriamycin in human neoplasia
49. Intrahepatic arterial administration of 4′-epidoxorubicin in advanced cancer patients. A pharmacokinetic study
50. High-dose intensity chemotherapy with epiadriamycin, cyclophosphamide and r-met HuG-CSF in breast cancer patients. Abstract 308
51. Studies on the mode of interaction of 4′-epiadriamycin and 4-demethoxydaunomycin with DNA
52. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment
53. Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma
54. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug
55. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer
56. Hemopoietic growth factors: a review
57. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture
58. High-dose epirubicin as initial therapy for advanced breast cancer. Abstract 166
59. Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration
60. Pharmacokinetics and toxicity of two schedules of high dose epirubicin
61. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin’s patients
62. A single community centre phase II trial of high dose epirubicin in stage IV breast cancer. Abstract 76
63. Pharmacokinetics of 4′-epidoxorubicin in man
64. Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin
65. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia
66. Phase II study of high-dose epirubicin in non-small cell lung cancer
67. Infusional anthracyclines: Is slow better? If so, why?